RANI (Rani Therapeutics Holdings) Short-Term Debt: $0.00 Mil (As of Mar. 2026)


RANI Rani Therapeutics Holdings Inc RANI
31 GF Score
Price $0.69
! 3 Warning Signs
View Full Analysis

What is Rani Therapeutics Holdings Short-Term Debt?

Rani Therapeutics Holdings RANI -1.58% 31 Short-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates RANI with a GF Score™ of 31/100. The stock has 3 warning signs investors should review.

Rani Therapeutics Holdings's Short-Term Debt for the quarter that ended in Mar. 2026 was $0.00 Mil.

Rani Therapeutics Holdings's quarterly Short-Term Debt declined from Sep. 2025 ($13.54 Mil) to Dec. 2025 ($0.00 Mil) but then stayed the same from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil).

Rani Therapeutics Holdings's annual Short-Term Debt increased from Dec. 2023 ($4.90 Mil) to Dec. 2024 ($15.00 Mil) but then declined from Dec. 2024 ($15.00 Mil) to Dec. 2025 ($0.00 Mil).

Rani Therapeutics Holdings Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Rani Therapeutics Holdings Short-Term Debt Related Terms

Rani Therapeutics Holdings Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Rani Therapeutics Holdings's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rani Therapeutics Holdings Short-Term Debt Chart

Rani Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial 0.00 0.00 4.90 15.00 0.00

Rani Therapeutics Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.00 15.00 13.54 0.00 0.00
RANI
31GF Score
Rani Therapeutics Holdings Inc RANI
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
Rani Therapeutics Holdings (RANI) has a Short-Term Debt of $0.00 Mil as of Mar. 2026.
Is Rani Therapeutics Holdings' Short-Term Debt too high?
Rani Therapeutics Holdings' current Short-Term Debt is $0.00 Mil. Overall, Rani Therapeutics Holdings has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Rani Therapeutics Holdings' Short-Term Debt compare to IBIO and RNTX?
Rani Therapeutics Holdings' Short-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Rani Therapeutics Holdings's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rani Therapeutics Holdings stock overvalued right now?
Rani Therapeutics Holdings (RANI) has a current Short-Term Debt of $0.00 Mil. The current Short-Term Debt is $0.00 Mil. Rani Therapeutics Holdings' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Rani Therapeutics Holdings (RANI), the current Short-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rani Therapeutics Holdings Business Description

Address 2051 Ringwood Avenue, San Jose, CA, USA, 95131
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
31GF Score

Get the complete analysis for RANI

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.69
Price